Celyad Oncology SA (CYAD) Reports Q1, Provides Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Celyad Oncology Reports First Quarter 2023 Financial Results and Recent Business Highlights
May 5, 2023 1:42 AM EDTPresentation of updated data on our multiplex shRNA platform, which allows targeting of up to four genes simultaneously Publication of results from the THINK trial, which provided proof-of-concept of our NKG2D-based CAR T-cell approach
MONT-SAINT-GUIBERT, Belgium--(BUSINESS WIRE)-- Regulatory News:
Celyad Oncology (Euronext & Nasdaq: CYAD) (the Company), a biotechnology company focused on innovative technologies for chimeric antigen receptor (CAR) T-cell therapies, today reports its financial results for the first quarter of 2023 and provides an update on recent business developments.
Celyad Oncology is now fully... More
